Levemir Sales Data
| Rank 30 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Levemir U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 30 | $424,186 | 9.34% | 3,382 | 0.86% |
| Q3 2013 | 30 ( 4) |
$387,958 | 6.54% | 3,353 | -4.34% |
| Q2 2013 | 34 (6) |
$364,156 | 8.40% | 3,505 | 4.69% |
| Q1 2013 | 40 | $335,926 | 8.81% | 3,348 | 4.92% |
| Q4 2012 | 40 (9) |
$308,726 | 12.31% | 3,191 | 7.91% |
| Q3 2012 | 49 (8) |
$274,892 | 7.66% | 2,957 | 4.30% |
| Q2 2012 | 57 (11) |
$255,344 | 6.58% | 2,835 | 3.02% |
| Q1 2012 | 68 (7) |
$239,576 | 9.25% | 2,752 | 8.69% |
| Q4 2011 | 75 (1) |
$219,295 | 8.66% | 2,532 | 5.02% |
| Q3 2011 | 76 ( 1) |
$201,824 | 1.83% | 2,411 | 4.10% |
| Q2 2011 | 75 (5) |
$198,189 | -0.11% | 2,316 | 23.65% |
| Q1 2011 | 80 | $198,403 | n/a | 1,873 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.